{"count": 57, "results": [{"_id": "35691993", "pmid": 35691993, "title": "Simvastatin inhibits prostatic hyperplasia in rats with metabolic syndrome.", "journal": "Int Urol Nephrol", "authors": ["Gong YM", "Wang X", "Liu S", "Hu XC", "Xu Y", "Huang T"], "date": "2022-09-01T00:00:00Z", "doi": "10.1007/s11255-022-03227-z", "meta_date_publication": "2022 Sep", "meta_volume": "54", "meta_issue": "9", "meta_pages": "2125-2131", "score": 50268.258, "text_hl": "@<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@Simvastatin@@@ inhibits @DISEASE_Prostatic_Hyperplasia @DISEASE_MESH:D011470 @@@prostatic hyperplasia@@@ in @SPECIES_10116 @@@rats@@@ with @<m>DISEASE_Metabolic_Syndrome</m> @DISEASE_MESH:D024821 @@@metabolic syndrome@@@.", "citations": {"NLM": "Gong YM, Wang X, Liu S, Hu XC, Xu Y, Huang T. Simvastatin inhibits prostatic hyperplasia in rats with metabolic syndrome. Int Urol Nephrol. 2022 Sep;54(9):2125-2131. PMID: 35691993", "BibTeX": "@article{35691993, title={Simvastatin inhibits prostatic hyperplasia in rats with metabolic syndrome.}, author={Gong YM and Wang X and Liu S and Hu XC and Xu Y and Huang T}, journal={Int Urol Nephrol}, volume={54}, number={9}, pages={2125-2131}}"}}, {"_id": "36005625", "pmid": 36005625, "pmcid": "PMC9414498", "title": "Metabolite Signature of Simvastatin Treatment Involves Multiple Metabolic Pathways", "journal": "Metabolites", "authors": ["Fernandes Silva L", "Ravi R", "Vangipurapu J", "Laakso M"], "date": "2022-08-16T00:00:00Z", "doi": "10.3390/metabo12080753", "meta_date_publication": "2022 Aug 16", "meta_volume": "12", "meta_issue": "8", "meta_pages": "", "score": 50259.438, "text_hl": "We performed a high-throughput liquid chromatography-tandem mass spectroscopy profiling on the effects of @<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@simvastatin@@@ treatment on 1098 metabolite concentrations in the participants of the METSIM (@<m>DISEASE_Metabolic_Syndrome</m> @DISEASE_MESH:D024821 @@@Metabolic Syndrome@@@ In Men) study including 1332 participants with @<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@simvastatin@@@ treatment and 6200 participants without statin treatment. ", "citations": {"NLM": "Fernandes Silva L, Ravi R, Vangipurapu J, Laakso M. Metabolite Signature of Simvastatin Treatment Involves Multiple Metabolic Pathways Metabolites. 2022 Aug 16;12(8):. PMID: 36005625", "BibTeX": "@article{36005625, title={Metabolite Signature of Simvastatin Treatment Involves Multiple Metabolic Pathways}, author={Fernandes Silva L and Ravi R and Vangipurapu J and Laakso M}, journal={Metabolites}, volume={12}, number={8}}"}}, {"_id": "32173640", "pmid": 32173640, "title": "Clinical effect of simvastatin combined with exercise training in the treatment of stationary chronic obstructive pulmonary disease complicated with metabolic syndrome.", "journal": "Pak J Pharm Sci", "authors": ["Liu J", "Jiang N", "Liu T", "Luo W"], "date": "2020-01-01T00:00:00Z", "meta_date_publication": "2020 Jan", "meta_volume": "33", "meta_issue": "1(Special)", "meta_pages": "437-440", "score": 50256.05, "text_hl": "Clinical effect of @<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@simvastatin@@@ combined with exercise training in the treatment of stationary @DISEASE_Pulmonary_Disease_Chronic_Obstructive @DISEASE_MESH:D029424 @@@chronic obstructive pulmonary disease@@@ complicated with @<m>DISEASE_Metabolic_Syndrome</m> @DISEASE_MESH:D024821 @@@metabolic syndrome@@@.", "citations": {"NLM": "Liu J, Jiang N, Liu T, Luo W. Clinical effect of simvastatin combined with exercise training in the treatment of stationary chronic obstructive pulmonary disease complicated with metabolic syndrome. Pak J Pharm Sci. 2020 Jan;33(1(Special)):437-440. PMID: 32173640", "BibTeX": "@article{32173640, title={Clinical effect of simvastatin combined with exercise training in the treatment of stationary chronic obstructive pulmonary disease complicated with metabolic syndrome.}, author={Liu J and Jiang N and Liu T and Luo W}, journal={Pak J Pharm Sci}, volume={33}, number={1(Special)}, pages={437-440}}"}}, {"_id": "35268685", "pmid": 35268685, "pmcid": "PMC8911959", "title": "Natural and Synthetic Agents Targeting Reactive Carbonyl Species against Metabolic Syndrome", "journal": "Molecules", "authors": ["Behl T", "Gupta A", "Chigurupati S", "Singh S", "Sehgal A", "Badavath VN", "Alhowail A", "Mani V", "Bhatia S", "Al-Harrasi A", "Bungau S"], "date": "2022-02-27T00:00:00Z", "doi": "10.3390/molecules27051583", "meta_date_publication": "2022 Feb 27", "meta_volume": "27", "meta_issue": "5", "meta_pages": "", "score": 50253.203, "text_hl": "From the available data, it may be emphasized that various synthetic agents, such as carnosine and @<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@simvastatin@@@, and natural agents, such as @CHEMICAL_Polyphenols @CHEMICAL_MESH:D059808 @@@polyphenols@@@ and @CHEMICAL_Terpenes @CHEMICAL_MESH:D013729 @@@terpenoids@@@, can become a drug of choice in the therapeutic management for combating @<m>DISEASE_Metabolic_Syndrome</m> @DISEASE_MESH:D024821 @@@metabolic syndromes@@@ that involve RCS in their pathophysiology. ", "citations": {"NLM": "Behl T, Gupta A, Chigurupati S, Singh S, Sehgal A, Badavath VN, Alhowail A, Mani V, Bhatia S, Al-Harrasi A, Bungau S. Natural and Synthetic Agents Targeting Reactive Carbonyl Species against Metabolic Syndrome Molecules. 2022 Feb 27;27(5):. PMID: 35268685", "BibTeX": "@article{35268685, title={Natural and Synthetic Agents Targeting Reactive Carbonyl Species against Metabolic Syndrome}, author={Behl T and Gupta A and Chigurupati S and Singh S and Sehgal A and Badavath VN and Alhowail A and Mani V and Bhatia S and Al-Harrasi A and Bungau S}, journal={Molecules}, volume={27}, number={5}}"}}, {"_id": "36902342", "pmid": 36902342, "pmcid": "PMC10003121", "title": "Simvastatin Improves Benign Prostatic Hyperplasia: Role of Peroxisome-Proliferator-Activated Receptor-gamma and Classic WNT/beta-Catenin Pathway", "journal": "Int J Mol Sci", "authors": ["Wang Z", "Yang S", "Li Y", "Zhou Y", "Liu D", "Liu J", "DiSanto ME", "Zhang X"], "date": "2023-03-03T00:00:00Z", "doi": "10.3390/ijms24054911", "meta_date_publication": "2023 Mar 3", "meta_volume": "24", "meta_issue": "5", "meta_pages": "", "score": 50252.812, "text_hl": "...@<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@SV@@@ is one of the established statins for the treatment of @<m>DISEASE_Metabolic_Syndrome</m> @DISEASE_MESH:D024821 @@@MetS@@@/@DISEASE_Hyperlipidemias @DISEASE_MESH:D006949 @@@hyperlipidemia@@@. ", "citations": {"NLM": "Wang Z, Yang S, Li Y, Zhou Y, Liu D, Liu J, DiSanto ME, Zhang X. Simvastatin Improves Benign Prostatic Hyperplasia: Role of Peroxisome-Proliferator-Activated Receptor-gamma and Classic WNT/beta-Catenin Pathway Int J Mol Sci. 2023 Mar 3;24(5):. PMID: 36902342", "BibTeX": "@article{36902342, title={Simvastatin Improves Benign Prostatic Hyperplasia: Role of Peroxisome-Proliferator-Activated Receptor-gamma and Classic WNT/beta-Catenin Pathway}, author={Wang Z and Yang S and Li Y and Zhou Y and Liu D and Liu J and DiSanto ME and Zhang X}, journal={Int J Mol Sci}, volume={24}, number={5}}"}}, {"_id": "33608711", "pmid": 33608711, "pmcid": "PMC8266622", "title": "Simvastatin Augmentation for Patients With Early-Phase Schizophrenia-Spectrum Disorders: A Double-Blind, Randomized Placebo-Controlled Trial", "journal": "Schizophr Bull", "authors": ["Sommer IE", "Gangadin SS", "de Witte LD", "Koops S", "van Baal C", "Bahn S", "Drexhage H", "van Haren NEM", "Veling W", "Bruggeman R", "Martens P", "Wiersma S", "Veerman SRT", "Grootens KP", "van Beveren N", "Kahn RS", "Begemann MJH"], "date": "2021-07-08T00:00:00Z", "doi": "10.1093/schbul/sbab010", "meta_date_publication": "2021 Jul 8", "meta_volume": "47", "meta_issue": "4", "meta_pages": "1108-1115", "score": 50250.625, "text_hl": "Moreover, @<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@simvastatin@@@ reduces @<m>DISEASE_Metabolic_Syndrome</m> @DISEASE_MESH:D024821 @@@metabolic syndrome@@@, a pivotal factor increasing mortality in @DISEASE_Schizophrenia_Spectrum_and_Other_Psychotic_Disorders @DISEASE_MESH:D019967 @@@SSD@@@. ", "citations": {"NLM": "Sommer IE, Gangadin SS, de Witte LD, Koops S, van Baal C, Bahn S, Drexhage H, van Haren NEM, Veling W, Bruggeman R, Martens P, Wiersma S, Veerman SRT, Grootens KP, van Beveren N, Kahn RS, Begemann MJH. Simvastatin Augmentation for Patients With Early-Phase Schizophrenia-Spectrum Disorders: A Double-Blind, Randomized Placebo-Controlled Trial Schizophr Bull. 2021 Jul 8;47(4):1108-1115. PMID: 33608711", "BibTeX": "@article{33608711, title={Simvastatin Augmentation for Patients With Early-Phase Schizophrenia-Spectrum Disorders: A Double-Blind, Randomized Placebo-Controlled Trial}, author={Sommer IE and Gangadin SS and de Witte LD and Koops S and van Baal C and Bahn S and Drexhage H and van Haren NEM and Veling W and Bruggeman R and Martens P and Wiersma S and Veerman SRT and Grootens KP and van Beveren N and Kahn RS and Begemann MJH}, journal={Schizophr Bull}, volume={47}, number={4}, pages={1108-1115}}"}}, {"_id": "34365791", "pmid": 34365791, "title": "The Novel Interplay between Commensal Gut Bacteria and Metabolites in Diet-Induced Hyperlipidemic Rats Treated with Simvastatin.", "journal": "J Proteome Res", "authors": ["Zhang S", "Yuan L", "Li H", "Han L", "Jing W", "Wu X", "Ullah S", "Liu R", "Wu Y", "Xu J"], "date": "2022-03-04T00:00:00Z", "doi": "10.1021/acs.jproteome.1c00252", "meta_date_publication": "2022 Mar 4", "meta_volume": "21", "meta_issue": "3", "meta_pages": "808-821", "score": 50250.215, "text_hl": "@DISEASE_Hyperlipidemias @DISEASE_MESH:D006949 @@@Hyperlipidemia@@@ is one kind of @<m>DISEASE_Metabolic_Syndrome</m> @DISEASE_MESH:D024821 @@@metabolic syndrome@@@ for which the treatment commonly includes @<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@simvastatin@@@ (@<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@SV@@@). ", "citations": {"NLM": "Zhang S, Yuan L, Li H, Han L, Jing W, Wu X, Ullah S, Liu R, Wu Y, Xu J. The Novel Interplay between Commensal Gut Bacteria and Metabolites in Diet-Induced Hyperlipidemic Rats Treated with Simvastatin. J Proteome Res. 2022 Mar 4;21(3):808-821. PMID: 34365791", "BibTeX": "@article{34365791, title={The Novel Interplay between Commensal Gut Bacteria and Metabolites in Diet-Induced Hyperlipidemic Rats Treated with Simvastatin.}, author={Zhang S and Yuan L and Li H and Han L and Jing W and Wu X and Ullah S and Liu R and Wu Y and Xu J}, journal={J Proteome Res}, volume={21}, number={3}, pages={808-821}}"}}, {"_id": "40427477", "pmid": 40427477, "title": "Protective Effects of Lotus Seedpod Extract on Hepatic Lipid and Glucose Metabolism via AMPK-Associated Mechanisms in a Mouse Model of Metabolic Syndrome and Oleic Acid-Induced HepG2 Cells.", "journal": "Antioxidants (Basel)", "authors": ["Lin HH", "Yu PR", "Tseng CY", "Lee MS", "Chen JH"], "date": "2025-05-16T00:00:00Z", "doi": "10.3390/antiox14050595", "meta_date_publication": "2025 May 16", "meta_volume": "14", "meta_issue": "5", "meta_pages": "", "score": 50243.7, "text_hl": "Adipokines, proinflammatory cytokines, liver @CHEMICAL_Fats @CHEMICAL_MESH:D005223 @@@fat@@@ droplets, and peri-portal @DISEASE_Fibrosis @DISEASE_MESH:D005355 @@@fibrosis@@@ were analyzed to clarify the mechanism of @<m>DISEASE_Metabolic_Syndrome</m> @DISEASE_MESH:D024821 @@@MetS.@@@ LSE significantly reduced the HFD/@CHEMICAL_Streptozocin @CHEMICAL_MESH:D013311 @@@STZ@@@-induced @<m>DISEASE_Metabolic_Syndrome</m> @DISEASE_MESH:D024821 @@@MetS@@@ markers better than @<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@simvastatin@@@, as demonstrated by hypoglycemic, hypolipidemic, antioxidant, and anti-@DISEASE_Inflammation @DISEASE_MESH:D007249 @@@inflammatory@@@ effects. ", "citations": {"NLM": "Lin HH, Yu PR, Tseng CY, Lee MS, Chen JH. Protective Effects of Lotus Seedpod Extract on Hepatic Lipid and Glucose Metabolism via AMPK-Associated Mechanisms in a Mouse Model of Metabolic Syndrome and Oleic Acid-Induced HepG2 Cells. Antioxidants (Basel). 2025 May 16;14(5):. PMID: 40427477", "BibTeX": "@article{40427477, title={Protective Effects of Lotus Seedpod Extract on Hepatic Lipid and Glucose Metabolism via AMPK-Associated Mechanisms in a Mouse Model of Metabolic Syndrome and Oleic Acid-Induced HepG2 Cells.}, author={Lin HH and Yu PR and Tseng CY and Lee MS and Chen JH}, journal={Antioxidants (Basel)}, volume={14}, number={5}}"}}, {"_id": "32335402", "pmid": 32335402, "title": "Testosterone concentrations and risk of cardiovascular events in androgen-deficient men with atherosclerotic cardiovascular disease.", "journal": "Am Heart J", "authors": ["Boden WE", "Miller MG", "McBride R", "Harvey C", "Snabes MC", "Schmidt J", "McGovern ME", "Fleg JL", "Desvigne-Nickens P", "Anderson T", "Kashyap M", "Probstfield JL"], "date": "2020-06-01T00:00:00Z", "doi": "10.1016/j.ahj.2020.03.016", "meta_date_publication": "2020 Jun", "meta_volume": "224", "meta_issue": "", "meta_pages": "65-76", "score": 50232.777, "text_hl": "OBJECTIVES: Among male subjects in the AIM-HIGH Trial with @<m>DISEASE_Metabolic_Syndrome</m> @DISEASE_MESH:D024821 @@@metabolic syndrome@@@ and low baseline levels of high-density lipoprotein (HDL)-cholesterol who were randomized to @CHEMICAL_Niacin @CHEMICAL_MESH:D009525 @@@niacin@@@ or placebo plus @<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@simvastatin@@@, we examined the relationship between low baseline @CHEMICAL_Testosterone @CHEMICAL_MESH:D013739 @@@testosterone@@@ (T) concentrations and subsequent @DISEASE_Cardiovascular_Diseases @DISEASE_MESH:D002318 @@@CV@@@ outcomes during a mean 3-year follow-up. ", "citations": {"NLM": "Boden WE, Miller MG, McBride R, Harvey C, Snabes MC, Schmidt J, McGovern ME, Fleg JL, Desvigne-Nickens P, Anderson T, Kashyap M, Probstfield JL. Testosterone concentrations and risk of cardiovascular events in androgen-deficient men with atherosclerotic cardiovascular disease. Am Heart J. 2020 Jun;224():65-76. PMID: 32335402", "BibTeX": "@article{32335402, title={Testosterone concentrations and risk of cardiovascular events in androgen-deficient men with atherosclerotic cardiovascular disease.}, author={Boden WE and Miller MG and McBride R and Harvey C and Snabes MC and Schmidt J and McGovern ME and Fleg JL and Desvigne-Nickens P and Anderson T and Kashyap M and Probstfield JL}, journal={Am Heart J}, volume={224}, pages={65-76}}"}}, {"_id": "34039170", "pmid": 34039170, "title": "Resveratrol-mediated cardioprotection against myocardial ischemia-reperfusion injury was revoked by statin-induced mitochondrial alterations.", "journal": "Drug Chem Toxicol", "authors": ["C Vedarathinam R", "Rajkumar Y", "Vetriselvan P", "Prem PN", "Ganapathy A", "Kurian GA"], "date": "2022-09-01T00:00:00Z", "doi": "10.1080/01480545.2021.1929285", "meta_date_publication": "2022 Sep", "meta_volume": "45", "meta_issue": "5", "meta_pages": "2276-2284", "score": 50230.203, "text_hl": "Male Wistar @SPECIES_10116 @@@rats@@@ were used in this study, and statin-induced @<m>DISEASE_Metabolic_Syndrome</m> @DISEASE_MESH:D024821 @@@cardiac metabolic alterations@@@ were monitored after the administration of @<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@simvastatin@@@ (80 mg/kg). ", "citations": {"NLM": "C Vedarathinam R, Rajkumar Y, Vetriselvan P, Prem PN, Ganapathy A, Kurian GA. Resveratrol-mediated cardioprotection against myocardial ischemia-reperfusion injury was revoked by statin-induced mitochondrial alterations. Drug Chem Toxicol. 2022 Sep;45(5):2276-2284. PMID: 34039170", "BibTeX": "@article{34039170, title={Resveratrol-mediated cardioprotection against myocardial ischemia-reperfusion injury was revoked by statin-induced mitochondrial alterations.}, author={C Vedarathinam R and Rajkumar Y and Vetriselvan P and Prem PN and Ganapathy A and Kurian GA}, journal={Drug Chem Toxicol}, volume={45}, number={5}, pages={2276-2284}}"}}]}